The further de-rating in shares of Medifast post the company's Q2 results offers an attractive entry point, especially as buybacks complement the company's underlying sales and margin expansion, Jefferies analyst Stephanie Wissink tells investors in a research note. The analyst is "puzzled" by the price action, noting Medifast has posted consistent quarterly results and that estimates "keep edging higher." Further, she sees the potential for the company to over-deliver on short- and long-term targets. Wissink keeps a Buy rating on Medifast with a $160 price target.